# Scale-up centers for innovative biologic small-batch production Public-private manufacturing-innovation institutes that operate shared pilot- and demonstration-scale biomanufacturing facilities, letting a biologic developer run small-batch production and prove out a process before committing capital to a dedicated commercial-scale plant. Source: https://en.bioecon.ru/technology/biologic-scale-up-centers/ Updated: 2026-08-18 ## Overview and value chain Markers: [EC: Shared pilot- and demonstration-scale biomanufacturing testbeds and training | OECD: Biopharmaceutical manufacturing innovation | Regulator: FDA (US), EMA (EU)] Scale-up centers for innovative biologic small-batch production operate shared pilot- and demonstration-scale facilities that let a developer prove out a manufacturing process before committing capital to a dedicated commercial-scale plant. NIIMBL, the US National Institute for Innovation in Manufacturing Biopharmaceuticals, announced 8 new technology and workforce projects in May 2026, including an enhanced end-to-end manufacturing testbed for fast, flexible drug-substance manufacturing using state-of-the-art process equipment, sensors and controls. BioMADE expanded its biomanufacturing pilot-plant network with a new $40M facility in Iowa — its third in a national network — and finalized a $132M national-security investment in a demonstration-scale biomanufacturing facility in Minnesota. NIBRT, Ireland's National Institute for Bioprocessing Research and Training, published its Mid-Year Training Catalogue for 2026 covering all training options for the remainder of the year and launched a Digital Academy delivering a structured digitalisation curriculum built specifically for biopharma. Fraunhofer IAP develops tailored yeast strains and scalable bioprocesses for the industrial bioeconomy and operates the Biocampus Multipilot facility in Straubing, Germany, a multi-purpose demonstration plant built specifically to bridge lab scale and industrial production. The key directions of biologic scale-up centers are: 1. **Shared pilot-plant access:** operating physical testbed and pilot-plant facilities that a developer can access without building its own, de-risking the jump from lab to commercial scale. 2. **Demonstration-scale process validation:** running a process at demonstration scale to validate it works reliably before a larger capital commitment to full commercial-scale manufacturing. 3. **Workforce training and digitalisation curricula:** structured training programs — including on manufacturing digitalisation — that build the skilled workforce a scaled-up biomanufacturing sector needs. 4. **National-security and public-investment-backed capacity:** public-private funding structures, including national-security-linked investment, building shared capacity that benefits an entire domestic biomanufacturing sector rather than one company. ### Sectoral value chain ``` [Lab-scale process development] ──> [Pilot-scale testbed access] ──> [Demonstration-scale validation] │ (Workforce training & digitalisation) │ [Commercial-scale readiness] <──── [Tech-transfer to commercial facility] <─── [Process data package compilation] ``` ### Value chain levels | Level | Description | Key inputs/outputs | |:---|:---|:---| | **Lab-scale process development** | Developing the biologic manufacturing process at lab bench scale. | **In:** Lab-scale process protocol.
**Out:** Candidate process ready for scale-up. | | **Pilot-scale testbed access** | Accessing a shared pilot-plant facility to run the process at pilot scale. | **In:** Candidate process ready for scale-up.
**Out:** Pilot-scale run data. | | **Demonstration-scale validation** | Running the process at demonstration scale to validate reliability before commercial commitment. | **In:** Pilot-scale run data.
**Out:** Demonstration-scale validation data. | | **Process data package compilation** | Compiling the pilot and demonstration data into a technology-transfer package. | **In:** Demonstration-scale validation data.
**Out:** Technology-transfer data package. | | **Tech-transfer to commercial facility** | Transferring the validated process to a dedicated commercial-scale manufacturing facility. | **In:** Technology-transfer data package.
**Out:** Commercial-facility process transfer. | | **Commercial-scale readiness** | Confirming the process runs reliably at full commercial scale, informed by the earlier pilot/demonstration work. | **In:** Commercial-facility process transfer.
**Out:** Commercial-scale production readiness. | Cross-cutting technologies of the sector: - **Pilot- and demonstration-scale biomanufacturing:** shared testbed and pilot-plant facilities that let a biologic developer run small-batch production at pilot or demonstration scale before committing capital to a dedicated commercial-scale facility. - **Public-private manufacturing-innovation institutes:** consortia combining government, industry and academic funding to build and operate shared biomanufacturing testbeds, training programs and scale-up facilities that no single company would build alone. --- ## US The United States hosts two federally-linked manufacturing-innovation institutes building shared biomanufacturing capacity across a national facility network. ### NIIMBL's end-to-end testbed enhancement, BioMADE's national pilot-plant network - **NIIMBL:** announced 8 new technology and workforce projects in May 2026, including an enhanced end-to-end manufacturing testbed for fast, flexible drug-substance manufacturing. - **BioMADE:** expanded its biomanufacturing pilot-plant network with a new $40M Iowa facility (its third nationally) and finalized a $132M national-security-linked investment in a demonstration-scale facility in Minnesota. --- ## CN China is covered qualitatively rather than by a live-screened Chinese institute: candidate Chinese biologic scale-up centers searched during this screen returned no confirming 2026 source, so no Chinese institute is tabled below. Chinese biologic developers typically scale up through domestic CDMO capacity or university-affiliated pilot facilities rather than a confirmed distinct public-private scale-up institute of this type. ### No confirmed domestic scale-up institute of this type; CDMO capacity and university pilot facilities cover the gap - **CDMO and university pilot facilities:** Chinese biologic developers typically access pilot-scale capacity through domestic CDMOs or university-affiliated facilities rather than a confirmed distinct public-private manufacturing-innovation institute. - **Domestic gap:** no China-headquartered institute of this specific public-private scale-up-center type confirmed by a live 2026 source was found during this screen. --- ## EU Ireland and Germany host leading European biomanufacturing training and scale-up institutes, spanning workforce development to pilot-plant infrastructure. ### NIBRT's digitalisation curriculum, Fraunhofer IAP's Biocampus Multipilot facility - **NIBRT:** published its Mid-Year Training Catalogue for 2026 and launched a Digital Academy delivering a structured digitalisation curriculum built specifically for biopharma manufacturing. - **Fraunhofer IAP:** develops tailored yeast strains and scalable bioprocesses for the industrial bioeconomy and operates the Biocampus Multipilot demonstration plant in Straubing, built specifically to bridge lab scale and industrial production. --- ## Leading companies and research institutes | Company / Institute | Country | Key products / platforms | Tech features | Status 2026 | |:---|:---|:---|:---|:---| | **NIIMBL** | 🇺🇸 USA | End-to-end manufacturing testbed | 8 new 2026 technology/workforce projects | research | | **BioMADE** | 🇺🇸 USA | National pilot-plant network | $40M Iowa + $132M Minnesota facilities | research | | **NIBRT** | 🇮🇪 Ireland | Training catalogue, Digital Academy | Structured biopharma digitalisation curriculum | research | | **Fraunhofer IAP** | 🇩🇪 Germany | Biocampus Multipilot facility | Lab-to-industrial-scale demonstration plant | research | --- ## Tech stack and innovations The biologic scale-up center technology stack combines shared physical infrastructure with an emerging digitalisation and workforce layer: 1. **Shared testbed infrastructure investment:** - BioMADE's $40M and $132M facility investments show public-private capital building shared pilot and demonstration capacity at a scale few single companies would fund alone. 2. **End-to-end testbed enhancement:** - NIIMBL's 2026 testbed enhancement targets fast, flexible drug-substance manufacturing with state-of-the-art process equipment, sensors and controls. 3. **Structured digitalisation training:** - NIBRT's Digital Academy delivers a curriculum specifically built to prepare a biopharma manufacturing workforce for digitalized operations, not generic IT training. --- ## Value chains and production pipelines ### Industrial pipeline for biologic manufacturing scale-up ``` ┌───────────────────────────┐ ┌───────────────────────────┐ │ 1. Lab-scale process │ ───> │ 2. Pilot-scale testbed │ │ development │ │ access │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 4. Process data package │ <─── │ 3. Demonstration-scale │ │ compilation │ │ validation │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 5. Tech-transfer to │ ───> │ 6. Commercial-scale │ │ commercial facility │ │ readiness │ └───────────────────────────┘ └───────────────────────────┘ ``` #### Stage 1: Lab-scale process development The biologic manufacturing process is developed at lab bench scale before any pilot-facility engagement. #### Stage 2: Pilot-scale testbed access The developer accesses a shared pilot-plant facility to run the process at pilot scale. #### Stage 3: Demonstration-scale validation The process is run at demonstration scale to validate reliability before a larger capital commitment. #### Stage 4: Process data package compilation Pilot and demonstration-scale data are compiled into a technology-transfer package. #### Stage 5: Tech-transfer to commercial facility The validated process is transferred to a dedicated commercial-scale manufacturing facility. #### Stage 6: Commercial-scale readiness The process is confirmed to run reliably at full commercial scale, informed directly by the earlier pilot and demonstration work.